Etid klinik pou Sipwa nan Mississippi
11 etid pou Sipwa ap chèche patisipan nan sit nan Mississippi.
Vil nan Mississippi
Tèks ofisyèl etid la (Anglè)
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
- Dynamed Clinical Research, LP d/b/a DM Clinical Research, Gulfport
Ap rekriteFaz 3
Laj 6 a 17 · Tout sèks · Mizajou Sep 24, 2026 · NCT06672549Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- Jackson Heart Clinic, Jackson
- Cardiology Associates of North Mississippi, Tupelo
Ap rekriteFaz 3
Laj 45 a 99 · Tout sèks · Mizajou Sep 22, 2026 · NCT07037433A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
- Research Site, Fayette
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07784270A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Gulfport
- AURORA-2 Clinical Site, Jackson
- AURORA-2 Clinical Site, Olive Branch
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT07743450A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
- AURORA-1 Clinical Site, Gulfport
- AURORA-1 Clinical Site, Jackson
- AURORA-1 Clinical Site, Olive Branch
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT07743463A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
- Olive Branch Family Medical Center, Olive Branch
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT07351058A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
- DelRicht Research at Gulfport Memorial, Gulfport
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT07351045A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
- ACCOMPLISH-2 Research Site, Gulfport
- ACCOMPLISH-2 Research Site, Ridgeland
Ap rekriteFaz 3Volontè an sante akeyi
Laj 18 a 79 · Tout sèks · Mizajou Sep 11, 2026 · NCT07654374Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
- Prime Health and Wellness Sky Clinical Research Network Group, Fayette
Ap rekriteFaz 3
Laj 18 a 99 · Tout sèks · Mizajou Sep 3, 2026 · NCT07684235Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
- Sky Integrative Medical Center, Ridgeland
Ap rekriteFaz 3
Laj 18 a 99 · Tout sèks · Mizajou Aug 27, 2026 · NCT07575399Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
- ACCOMPLISH-1 Research Site, Gulfport
- ACCOMPLISH-1 Research Site, Ridgeland
Ap rekriteFaz 3
Laj 18 a 79 · Tout sèks · Mizajou Aug 10, 2026 · NCT07654361Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.